EP 1300

Drug Profile

EP 1300

Alternative Names: EP1300; Malaria DNA vaccine - KAEL-GemVax

Latest Information Update: 05 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA); Pharmexa-Epimmune
  • Developer KAEL-GemVax; National Institutes of Health (USA)
  • Class Antimalarials; DNA vaccines; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 19 Jan 2012 The National Institute of Allergy and Infectious Diseases completes enrolment in a phase I trial for Malaria in USA (NCT01169077)
  • 23 Sep 2010 Phase-I clinical trials in Malaria prevention in USA (Parenteral)
  • 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top